Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAMAGE-A1: FH-MagIC TCR-T Cells + Atezolizumab in MAGE-A1+ Cancers
NCT04639245Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FH-MagIC TCR-T cells in triple-negative breast cancer (TNBC), urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Count of Participants That Experienced Treatment-related Unexpected Grade 3 or Higher Adverse Events and Best Overall Response. Started Jul 2021; status: terminated.
02
Drugs
FH-MagIC TCR-T cells
03
Conditions
triple-negative breast cancer (TNBC)urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04639245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639245.